Key result
CT-based scaling analysis revealed that patients with metabolic syndrome had a significantly higher length-volume scaling power law coefficient than controls (27.0 vs 19.9 cm24/3), providing a quantitative index for diffuse CAD.
Why the study?
Does scaling power law analysis of coronary CT angiography differentiate diffuse coronary artery disease in patients with metabolic syndrome compared to controls?
Case-Control (n=120)
No
Does scaling power law analysis of coronary CT angiography differentiate diffuse coronary artery disease in patients with metabolic syndrome compared to controls?
Absolute Event Rate: 27% vs 19.9%
p-value: p=<.05
Retrospective scaling analysis of coronary CT angiography provides a quantitative rationale for diagnosing diffuse CAD, showing significant differences in length-volume power law coefficients between patients with metabolic syndrome and controls.
May aid diffuse CAD detection in metabolic syndrome; hypothesis-generating and requires prospective validation.
PURPOSE: To provide proof of concept for a diagnostic method to assess diffuse coronary artery disease (CAD) on the basis of coronary computed tomography (CT) angiography. MATERIALS AND METHODS: The study was approved by the Cleveland Clinic Institutional Review Board, and all subjects gave informed consent. Morphometric data from the epicardial coronary artery tree, determined with CT angiography in 120 subjects (89 patients with metabolic syndrome and 31 age- and sex-matched control subjects) were analyzed on the basis of the scaling power law. Results obtained in patients with metabolic syndrome and control subjects were compared statistically. RESULTS: The mean lumen cross-sectional area (ie, lumen cross-sectional area averaged over each vessel of an epicardial coronary artery tree) and sum of intravascular volume in patients with metabolic syndrome (0.039 cm(2) ± 0.015 [standard deviation] and 2.71 cm(3) ± 1.75, respectively) were significantly less than those in control subjects (0.054 cm(2)± 0.015 and 3.29 cm(3)± 1.77, respectively; P < .05). The length-volume power law showed coefficients of 27.0 cm(-4/3) ± 9.0 (R(2) = 0.91 ± 0.08) for patients with metabolic syndrome and 19.9 cm(-4/3) ± 4.3 (R(2) = 0.92 ± 0.07) for control subjects (P < .05). The probability frequency shows that more than 65% of patients with metabolic syndrome had a coefficient of 23 or more for the length-volume scaling power law, whereas approximately 90% of the control subjects had a coefficient of less than 23. CONCLUSION: The retrospective scaling analysis provides a quantitative rationale for diagnosis of diffuse CAD.
No takes yet. Share an insight, caveat, or question.
Huo et al. (2013) conducted a case-control in Metabolic syndrome (high risk for diffuse coronary artery disease) (n=120). CT-based scaling power law analysis vs. Control subjects without metabolic syndrome was evaluated on Length-volume scaling power law coefficient (KLV) (p=<.05). CT-based scaling analysis revealed that patients with metabolic syndrome had a significantly higher length-volume scaling power law coefficient than controls (27.0 vs 19.9 cm24/3), providing a quantitative index for diffuse CAD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: